Chronic Kidney Disease Stage 3 Clinical Trial
Official title:
Effect of Phosphate Binders on FGF-23 During Calcitriol Administration in CKD Stage 3 Patients
Chronic kidney disease (CKD) is an established risk factor for cardiovascular morbidity and
mortality, as shown by common manifestations of left ventricular hypertrophy (LVH) and
arterial calcifications in CKD patients. Fibroblast growth factor-23(FGF-23) is a recently
identified phosphaturic hormone that has been reported to be associated with the development
of secondary hyperparathyroidism, cardiovascular morbidity, mortality, CKD progression.
While vitamin D is the mainstay therapy in CKD mineral bone disease (CKD-MBD), increased
FGF-23 levels have been reported with vitamin D administration. The purpose of this study
was to investigate the effect of calcium carbonate when used in conjunction with calcitriol
on FGF-23.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05169411 -
Preserving Kidney Function in Children With Chronic Kidney Disease
|
N/A | |
| Terminated |
NCT03529071 -
Empowering Veterans to Communicate With Healthcare Providers
|
N/A | |
| Recruiting |
NCT03311321 -
Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients
|
N/A | |
| Active, not recruiting |
NCT05198284 -
Prospective Decision Impact Clinical Utility Trial of KidneyIntelX
|
||
| Recruiting |
NCT05797506 -
Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease
|
Phase 2 | |
| Recruiting |
NCT01709994 -
Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients
|
Phase 3 | |
| Active, not recruiting |
NCT05225454 -
The Life Style Patterns and the Development Trend of Chronic Diseases in Healthy and Sub-healthy Groups Were Analyzed by Using Data-mining Techniques
|
||
| Completed |
NCT04012957 -
Desidustat in the Treatment of Anemia in CKD
|
Phase 3 | |
| Completed |
NCT03242252 -
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
|
Phase 3 | |
| Recruiting |
NCT01509716 -
Assessing Perceived Versus Actual Knowledge and Quality of Life in Pre-Dialysis Chronic Kidney Disease (CKD) Patients
|
N/A |